Yellow feverYellow fever is caused by a virus, which circulates between infected monkeys or humans and mosquitoes; the disease occurs in tropical regions of Africa and parts of South / Central America
Yellow fever (YF) is a viral disease transmitted by mosquitoes causing a spectrum of disease from mild to severe symptoms.
The risk of contracting yellow fever infection for travellers is related to a number of factors:
In general, yellow fever vaccination is recommended for all persons visiting countries where there is a risk of YF virus transmission.
Under the International Health Regulations (2005), an International Certificate of Vaccination or Prophylaxis for YF may be an entry requirement for some travellers to YF risk countries.
Certificate requirements may be either:
YF certificate requirements are not necessarily connected to the risk of disease for a traveller.
There is no treatment for YF disease. Care of an infected person is based on managing the symptoms.
Yellow fever (YF) is caused by a virus of the Flaviviridae family, which circulates between infected monkeys or humans and mosquitoes. The areas at risk for transmission of YF are in tropical regions of Africa and South America.
YF virus can cause an illness that results in jaundice (yellowing of the skin and eyes) and bleeding with severe damage to the major organs (e.g. liver, kidneys and heart). The mortality rate is high in those who develop severe disease.
YF is a vaccine preventable disease. In order to prevent the international spread of YF, under the International Health Regulations (IHR) (2005) , countries may require proof of vaccination, recorded in an International Certificate of Vaccination or Prophylaxis (ICVP). A Medical Letter of Exemption from vaccination may be taken into account by a receiving country, and can be considered in some circumstances.
YF is a risk in tropical parts of Africa, South America, eastern Panama in Central America and Trinidad in the Caribbean.
Areas with a ‘risk of YF transmission’ (also known as endemic) are countries (or areas within countries) where mosquito species known to transmit the disease are present and where the infection is reported in monkeys and/or humans.
Some areas are designated as ‘low’ risk; these are bordering endemic areas where there have been no confirmed reports of yellow fever in either monkeys or humans. Evidence of transmission in the past is uncertain or suggests low prevalence of infection. Transmission of YF virus in these areas is therefore considered unlikely .
Under-reporting, limitations in surveillance methods and misdiagnosis make estimating the burden of YF disease challenging . The World Health Organization (WHO) estimates 200,000 cases of YF and 30,000 deaths occur globally each year with the majority (90 percent) occurring in Africa. These estimates are based on studies from the early 1990s . However, a recent study of YF disease burden in Africa estimated there to be 130,000 (95% CI 51-380,000) cases of severe YF in 2013, resulting in 78,000 (95% CI 19-180,000) deaths .
Following a consultation on YF and international travel convened by the WHO in 2008, an expert working group considered the evidence for risk of YF transmission on a country by country basis [2, 5]. The results from this were used to develop vaccination recommendation maps that were first published in April 2011 and updated in 2013 [Americas] and 2015 [Africa]. Current as of September 2014, maps redeveloped by CDC, align with recommendations published by the World Health Organization (WHO).
These new vaccination recommendations result from an entirely new approach to protection of travellers against YF, and require healthcare providers to consider carefully the traveller’s potential exposure to YF and the safety of the vaccine .
Figures 1: Vaccine recommendation map for the Americas
Figures 2: Vaccine recommendation map for Africa
Current as of September 2014. These maps, which align with recommendations also published by the World Health Organization (WHO), are updated versions of the 2010 maps created by the Informal WHO Working Group on the Geographic Risk of Yellow Fever.
Please check our Country Information pages for individual country vaccine recommendations.
There may be lengthy periods between outbreaks of YF, nevertheless, in endemic areas, the virus may still be circulating, but at a level that is not picked up through surveillance. Risk areas should be considered as dynamic and subject to change; information about expansion of risk areas and current known outbreaks is published by the Pan American Health Organization (PAHO) and the WHO. Where verified information is available, details of recent outbreaks of YF can be found in our Outbreak Surveillance and Latest News pages.
Risk for travellers
The risk of contracting YF is determined by the following factors:
- travel destination
- intensity of YF transmission in area to be visited
- season of travel (most cases in travellers have occurred in the late rainy season to early dry season)
- duration of travel
- activities allowing exposure to mosquitoes
- immunisation status 
Although ongoing cases and outbreaks of YF occur in Africa and South America, the disease is preventable by vaccination and remains a very rare cause of illness in travellers. There were six recorded deaths from YF in European and American travellers between 1996 and 2010. Infections were acquired during trips to the Amazon Basin, Brazil, Côte d’Ivoire (Ivory Coast), the Gambia and Venezuela. None of these travellers were vaccinated against YF .
There have been no confirmed YF cases reported in the UK since 1930, when a laboratory worker contracted YF while working with the virus at the Hospital for Tropical Diseases in London .
Outbreak reports can be helpful when undertaking a risk assessment for travellers. However, it is important to acknowledge the limitations of such reports; case numbers and outbreaks may not accurately represent YF activity and reporting systems and the level of information that is sent to the WHO may differ between countries.
International Health Regulations (2005)
The International Health Regulations (IHR), which were revised and adopted by the World Health Assembly in 2005, were formulated to help prevent the international spread of disease, and in the context of international travel, do so with minimum disruption to trade and travel . Under Annex 7 of the IHR (2005), YF has been designated as an infection for which an International Certificate of Vaccination or Prophylaxis (ICVP) may be required for travellers as a condition of entry to a country. Other diseases may be designated as above if WHO put in place temporary recommendations as a result of declaring an outbreak a Public Health Emergency of International Concern. Currently YF and polio are the only diseases for which an ICVP may be required for entry into or exit from a country.
As of 11 July 2016, WHO states that the period of validity of the ICVP has changed from 10 years to the duration of the life of the person vaccinated. This applies to all ICVP for yellow fever vaccination, including certificates already issued, and new or duplicate certificates [9, 10].
Countries where YF does not occur, but where the mosquito vector and often the non-human primate hosts are present, are vulnerable to importation of YF and subsequent onward transmission within the local population. For these countries, YF vaccination may be an entry requirement for all travellers arriving from countries where there is a risk of YF transmission (often including airport transit).
Countries with risk of YF transmission may or may not require proof of YF vaccination from travellers. The absence of a requirement for YF vaccination does not necessarily mean that there is no risk of YF in the country, and YF immunisation may still be recommended for the protection of the individual traveller.
Member states are asked to submit details of their YF certificate requirements to WHO each year. Information is published annually by the WHO in International Travel and Health and details can be found on our Country Information pages.
When YF vaccine is required under IHR (2005), failure to provide a valid ICVP to the port health authorities could result in a traveller being quarantined, put under surveillance, or denied entry .
WHO states that valid certificates of vaccination presented by arriving travellers cannot be rejected on the grounds that more than ten years have passed since the date vaccination became effective as stated on the certificate; boosters or revaccination cannot be required .
If YF vaccination is contraindicated for medical reasons (including infants under 6 months of age), a Medical Letter of Exemption (MLoE) from vaccination can be issued by an authorised health worker (e.g.in the UK the UKYFVC Responsible Supervising Clinician, a nurse or pharmacist working at that centre, or a licensed health care professional otherwise supervising the medical care of the traveller).
Jungle primates (e.g. susceptible species of monkey) and humans are the hosts for the YF virus . The virus is transmitted via the bite of infected Aedes spp. (Africa and Americas) or Haemogogus spp. and Sabethes spp. (Central and South America only) mosquitoes. Only females of these mosquito species transmit the virus.
Transmission of YF occurs in three cycles:
- Jungle: occurring in tropical rainforests of Africa and South America. The transmission cycle occurs between monkeys and jungle breeding mosquitoes. Humans can become infected when they live or work in areas where this cycle occurs.
- Savannah (Africa only): occurs in the moist savannah regions of Africa where humans live and work in close proximity to the monkey population. The transmission cycle occurs between monkeys and humans, with spread via Aedes spp.
- Urban: following infection during the jungle cycle, infected humans can introduce the virus to urban areas where there is a high population density. Virus transmission occurs between humans in areas where the domesticated mosquito vector, Aedes aegypti (i.e. those that breed around human habitation) is present.
Aedes spp. mosquitoes are adapted to living in an urban (domestic) environment and breed in water collections provided by humans (e.g. vases, tyres and other receptacles); this species is active during daylight hours, and bite from dawn to dusk.
Haemagogous spp. and Sabethes spp. mosquitoes live in the forest canopy in Central and South America. These mosquitoes feed on monkeys and bite predominantly during the day. They can descend to ground level when the forest has been disturbed (e.g. during logging or during cultivation), where they may bite humans .
Once infected with the virus, the mosquito remains infectious for life (two to three months). Generally, mosquito species are most active at times of high rainfall, both in the jungle and urban environments. YF virus can survive very dry conditions in mosquito eggs, which hatch once a water collection is replenished. This can result in YF outbreaks in urban and rural areas, even during the drier months.
Signs and symptoms
YF varies in severity. The infection has an incubation period of three to six days. Initial symptoms include myalgia (muscle pain), pyrexia (high temperature), headache, anorexia (lack of appetite), nausea, and vomiting. In many patients there will be improvement in symptoms and gradual recovery three to four days after the onset of symptoms. Within 24 hours of an apparent recovery, 15 to 25 percent of patients progress to a more serious illness. This takes the form of an acute haemorrhagic fever, in which there may be bleeding from the mouth, eyes, ears, and stomach, pronounced jaundice (yellowing of the skin, from which the disease gets its name), and renal (kidney) damage. The patient develops shock and there is deterioration of major organ function; 20 to 50 percent of patients who develop this form of the disease do not survive . Infection results in lifelong immunity in those who recover.
Diagnosis and treatment
The preliminary diagnosis is based on the patient’s clinical features, places and dates of travel, and activities . Laboratory diagnosis is best performed by:
- Serologic assays to detect virus-specific IgM and IgG antibodies. Because of cross-reactivity between antibodies raised against other flaviviruses, more specific antibody testing, such as a plaque reduction neutralization test should be done to confirm the infection.
- Virus isolation or nucleic acid amplification tests performed early in the illness for YFV or YF viral RNA. However, by the time more overt symptoms are recognised, the virus or viral RNA is usually undetectable. Therefore, virus isolation and nucleic acid amplification should not be used for ruling out a diagnosis of YF .
There is no specific antiviral treatment. Intensive supportive nursing care and symptomatic management are the standard.
Preventing yellow fever
There are two methods to prevent YF: mosquito control and bite avoidance, and vaccination. A highly effective live, attenuated (weakened) YF vaccine has been available for more than 70 years . In general, vaccination is recommended for all persons visiting countries where there is a risk of YF virus transmission. Persons who travel to YF risk countries, without the benefit of vaccination should be advised of the risk of contracting YF and the potential for quarantine at the port of entry, depending on the country requirements for vaccination. They should also practise meticulous mosquito bite avoidance.
Country recommendations for YF vaccination
The recommendations for YF vaccination should be reviewed on our Country Information pages.
Indications for use of vaccine
- YF vaccine is indicated for susceptible adults and children aged nine months or older who need primary immunisation or booster vaccination against YF either:
– for personal protection
– or in order to comply with IHR (2005)
– or both (the requirement for vaccination against YF is not always
related to the risk of exposure to disease)
- Laboratory workers handling infective material
A careful assessment that balances the risk of disease with requirements for vaccination, taking into account the age and health status of traveller, needs to be performed prior to vaccination.
There is currently one licensed YF vaccine in the UK, Stamaril® (Sanofi Pasteur MSD). This contains an attenuated 17D strain of YF virus and protects against all strains of YF.
The Summary of Product Characteristics (SPC) for the vaccine should be consulted for specific information relating to the product.
|Vaccine||Schedule||Length of protection||Age range|
|Stamaril®||1 dose||At least 35 years and may be lifelong (*see below)||Minimum age 9 months. Seek medical advice for infants 6-8 months who are travelling to high risk area|
*Reinforcing immunisation (booster dose) should be offered a small subset of travellers who may be at continued risk see Public Health England guidance .
Around 90 percent of YF vaccine recipients achieve protective levels of neutralizing antibody within 10 days following primary vaccination .
YF vaccine should not be given to the following groups under any circumstances :
- Infants aged under six months
- Persons with a confirmed anaphylactic reaction to a previous dose of YF vaccine
- Persons with a confirmed anaphylactic reaction to any of the components of the vaccine
- Persons with a confirmed anaphylactic reaction to egg
- Persons who are immunocompromised due to a congenital condition, disease process or treatment (see )
- History of thymus disorder
For those with a febrile illness (fever) or who are acutely unwell, YF vaccination should be postponed until full recovery.
Where travel to YF risk areas is unavoidable, YF vaccination may be considered for the following groups:
- Breast feeding women
- Infants age six to eight months
- Individuals age 60 years and older
- HIV-infected individuals (with a CD4 count greater than 200 and a suppressed viral load, specialist advice should be sought)
- Pregnant women 
Individual risk assessment should take into account the risk of the disease at the destination versus the potential for adverse events following YF vaccination (which may be greater where certain underlying medical conditions exist). Expert opinion may be advisable.
Further information on precaution groups is available in Immunisation against infectious disease, Chapter Ch. 35. Yellow fever.
The 17D strain virus YF vaccine has been in use for more than 70 years. It is estimated that 500 million doses of the vaccine have been administered worldwide . Reactions to YF vaccine are usually mild and short lived. They include myalgia (muscle pain), headache, and low-grade fever, typically occurring during the first five to ten days post vaccination, and will affect 10-30% of recipients.
Serious adverse events are rare and fall into three main categories: hypersensitivity reactions, vaccine-associated neurologic disease (YEL-AND) and vaccine-associated viscerotropic disease (YEL-AVD).
The vaccine is propagated in chick embryos. The SPC for Stamaril® (the only YF vaccine used in the UK) lists sorbitol and lactose as excipients. Anaphylaxis as a result of sensitivity to either egg or other vaccine components, has recently been estimated to occur at an incidence of 1.8 cases/100,000 doses distributed (US data) .
Yellow Fever Vaccine-Associated Neurologic Disease (YEL-AND)
Post-vaccine encephalitis has been recognised as a rare event since the early use of the vaccine. Cases were reported in very young infants during the 1950s (when there was no age restriction for vaccine administration). In the 1960s, when vaccine use was restricted to babies aged over six months, reduced numbers of post vaccine encephalitis were reported .
Since 2001, a new pattern of neurologic adverse events (undesirable effects on the nervous system) has been recognised [18-20]. These events have been termed YF vaccine-associated neurologic disease (YEL-AND); the reporting has been estimated to be 0.8 cases per 100,000 doses distributed (US data) . The clinical presentation of neurologic events begins four to 23 days (median 14 days) following receipt of vaccine, with fever and headache that can progress to encephalitis (inflammation of the brain), or an autoimmune demyelinating disease (a disorder that can interrupt nerve transmission) with peripheral or central nervous involvement. Most patients will completely recover. Almost all cases have occurred in those receiving the vaccine for the first time with no underlying YF immunity .
Yellow Fever Vaccine-Associated Viscerotropic Disease (YEL-AVD)
YF vaccine-associated viscerotropic disease (YEL-AVD) is a syndrome of fever and multi-organ failure that resembles severe YF disease; it was first described in 2001 . As of March 2011, 65 cases of YEL-AVD had been reported worldwide; of the 65 cases, 41 (61 percent) died . Three cases have been reported in the United Kingdom, one in 1998 and two in 2000; all the UK cases survived .
Two to eight days (median four days) following vaccination, patients with YEL-AVD develop fever, malaise, headache, and myalgia that progress to hepatitis (inflammation of the liver), hypotension (low blood pressure), and multi-organ failure. Death has occurred in more than 60 percent of reported cases.
All reported cases of YEL-AVD have occurred in first-time vaccine recipients [7, 14].
YEL-AVD has been estimated to be reported in 0.4 cases per 100,000 doses distributed (US data) . For individuals who are aged 60 years and older, the risk for these serious adverse events increases several fold to approximately 1.8 cases per 100,000 doses distributed for YEL-AND and 1.4 cases per 100,000 doses distributed for YEL-AVD (US data) .
Advancing age (i.e. aged over 60 years) is, therefore a risk factor when considering YF vaccination; vaccine can be offered after careful risk assessment.
Additional documented risk factors for serious adverse events following YF vaccination are thymus disorder and thymectomy following a thymus disorder; YF vaccine should never be given to individuals with this medical history [15, 23].
There is no evidence that YEL-AVD is related to the vaccine virus reverting to a more virulent form (i.e. a form able to cause disease). Rather, these patterns of serious adverse events appear to be host-related (related to the individual vaccinated). Host risk factors such as genetic control of inflammation, are being actively investigated, but it is clear that those with existing thymus disease and older adults are at more risk [23-26].
Further information on adverse events following YF vaccine is available in Immunisation against infectious disease, Chapter Ch. 35. Yellow fever.
First Published : 24 Jul 2015
Last Updated :  06 Oct 2016
- World Health Organization. International Health Regulations (2005). Geneva: World Health Organization, 2005:1-60. [Accessed 2015]
- World Health Organization. Yellow fever risk mapping: Background for the Consultation on Yellow Fever and International Travel, 2010 (update September 2010). [Accessed 2015]
- Garske T, Van Kerkhove MD, Yactayo S, Ronveaux O, Lewis RF, et al. (2014) Yellow Fever in Africa: Estimating the Burden of Disease and Impact of Mass Vaccination from Outbreak and Serological Data. PLoS Med 11(5): e1001638. doi:10.1371/journal.pmed.1001638
- World Health Organization. Wkly Epidem Rec. Vaccines and vaccination against yellow fever: World Health Organization Position Paper, June 2013; 27, 88:269-284. [Accessed 2015]
- Jentes ES, Poumerol G, Gershman MD et al. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect Dis 2011; 11(8):622-632.
- National Travel Health Network and Centre. Clinical Update: changes to geographical risk area for yellow fever and recommendations for vaccination. 27 April 2011. [Accessed 2015]
- Monath TP, Gershman M, Staples JE, Barrett AD. Yellow fever vaccine Ch.38 In. Plotkin S, Orenstein W and Offit P (Eds). Vaccines 6th ed. Philadelphia, 2013
- Cook GC. Fatal yellow fever contracted at the Hospital for Tropical Diseases, London, UK, in 1930. Trans Roy Soc Trop Med Hyg 1994; 88 (6): 712-3.
- World Health Organization. International Travel and Health. Annex 1 – Update – as of 11 July 2016 Countries with risk of yellow fever transmission and countries requiring yellow fever vaccination. [Accessed 2016]
- World Health Organization. Amendment to International Health Regulations (2005). Annex 7 (yellow fever). 2016. [Accessed 2016]
- Young PR, Ng LFP, Hal RA et al. Arbovirus Infection Ch14. In: Farrar J, Hotez PK, Junhannss T et al (eds). Manson’s Tropical Diseases. 23rd Edn. Elsevier (Saunders). 2014.
- Service M. Medical Entomology for Students. 5th ed. New York. Cambridge University Press; 2012
- Monath T, Cetron M. Prevention of yellow fever in persons travelling to the tropics. Clin Infect Dis. 2002; 24:1369-1378.
- Centers for Disease Control and Prevention. Health Information for International Travel. 2016. [Accessed 2016]
- Public Health England. Yellow fever. Ch 35. In: Immunisation against infectious disease. [Accessed 2015]
- Monath TP 2001. Yellow fever: an update. Lancet Infect Dis 1: 11–20.
- Lindsey NP, Schroeder BA, Miller ER et al. Adverse event reports following yellow fever vaccination. Vaccine 2008; 26: 6077-6082
- Kitchener S. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX ((R)). Vaccine 2004; 22:2103-5.
- McMhaon AW. Eidex RB, Marfin AA et al. Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases. Vaccine 2007;25: 1727-1734
- Guimard T, Minjolle S, Polard E, et al. Short report: Incidence of yellow fever vaccine-associated neurotropic disease. Am J Trop Med Hyg 81:1141-3. 200913.
- Centers for Disease Control and Prevention. Adverse events associated with 17D-derived yellow fever vaccination -United States, 2001-2002. MMWR 2002; 51: 989-993. [Accessed 2015]
- Receveur MC, Bruyand M, Pistone T et al. Vaccination antiamarile: mise au point à propos des effets indésirables rares et graves [In French]. Médecine et Maladies Infectieuses 2009; 39(4):234-241.
- Barwick Eidex R, for the Yellow Fever Vaccine Safety Working Group. History of thymoma and yellow fever vaccination. Lancet 2004; 11-17; 364 (9438): 936.
- Hayes EB. Acute viscerotropic disease following vaccination against yellow fever. Transactions of the Royal Society of Tropical Medicine and Hygiene 2007; 101:967-971
- Barrett AD, Teuwen DE. Yellow fever vaccine – how does it work and why do rare cases of serious adverse events take place? Curr Opin Immunol. 21:308-13.2009
- Silva ML, Espírito-Santo LR, Martins MA. Clinical and Immunological Insights on Severe, Adverse Neurotropic and Viscerotropic Disease following 17D Yellow Fever Vaccination Clinical and Vaccine Immunology, Jan. 2010, 17(1). 118–126